GlassScriptPhysician profile
Douglas R Dodson
NPI 1861464844
$25,879.35
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Neuromusculoskeletal Medicine, Sports Medicine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,725 · 2020: $4,070 · 2021: $4,372 · 2022: $4,395 · 2023: $4,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $4,294 · Food and Beverage: $23.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $4,293.67 |
| Food and Beverage | $23.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyocera Medical Technologies, INC. | $16,828.86 | 2020-2023 | |
| Renovis Surgical Technologies, INC. | $8,699.48 | 2019 | |
| Abbott Laboratories | $288.87 | 2021 | |
| Depuy Synthes Sales INC. | $25.27 | 2019 | |
| Zimmer Biomet Holdings, INC. | $23.58 | 2023 | Gps III Platelet Concentration System |
| Orthofix Medical, INC. | $13.29 | 2021 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,778,472.83 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Dodson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.